Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer

Future Oncol. 2019 Sep;15(25):2943-2953. doi: 10.2217/fon-2018-0939. Epub 2019 Apr 30.


Aim: Little is known about recent treatment patterns among patients with unresected stage III NSCLC in the real world. This retrospective study used medical records from USA community oncology practices to address this knowledge gap. Materials & methods: Eligible patients were stage III NSCLC adults diagnosed between 1 January 2011 and 1 March 2016 without surgical resection. Treatment patterns were assessed across three progression intervals, from stage III diagnosis through third progression. Results: The most common regimen in interval 1 was platinum doublet chemotherapy + radiation therapy, in interval 2 was chemotherapy only, and in interval 3 was non-platinum chemotherapy monotherapy. Conclusion: Most patients were treated following national guidelines, but important unmet needs remain.

Keywords: community oncology; concurrent chemoradiation; real-world; sequential chemoradiation; treatment patterns; unmet need; unresected stage III NSCLC.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Anaplastic Lymphoma Kinase / genetics
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Combined Modality Therapy
  • Disease Progression
  • Disease-Free Survival
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Platinum / therapeutic use*
  • Proto-Oncogene Proteins p21(ras) / genetics


  • KRAS protein, human
  • Platinum
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • EGFR protein, human
  • ErbB Receptors
  • Proto-Oncogene Proteins p21(ras)